Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ILMN

Illumina, Inc.

Healthcare | Medical - Diagnostics & Research
$188.68 +66.61 (+54.57%) as of 2026-07-15 03:54 UTC
Market Cap$28.6B
Volume2.92M
EPS (TTM)$5.45

Illumina, Inc. (NASDAQ: ILMN) is a $28.6B medical - diagnostics & research company trading at $188.68 (+54.6% today) — 34.6× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 03:54 UTC.

52-Week Range
Low $120.60High $189.36

What Illumina, Inc. does

The company provides sequencing and array-based solutions for genetic and genomic analysis used by research centers, academic institutions, government laboratories, hospitals, and pharmaceutical and biotechnology companies. Its integrated portfolio includes sequencing systems, microarray systems, consumables, and analysis tools designed for various genomic applications and customer needs. The company was incorporated in California in April 1998 and reincorporated in Delaware in July 2000, with principal offices in San Diego, California.

Summarized from Illumina, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$188.68
Change (1D)+66.61 (+54.57%)
Market cap$28.6B
Volume2.92M shares
52-week range$120.60 – $189.36
Valuation
P/E (TTM)34.62×
EV/EBITDA28.80×
EPS (TTM)$5.45
Price/book10.48×
Return on equity31.22%
Debt/equity0.18
Returns
52-week return+56.4%
Revenue, margins & earnings
FY2021 Revenue: $3.24B — margin split not shown (non-operating gains)$3.24BFY2021FY2022 Revenue: $4.53B — margin split not shown (non-operating gains)$4.53BFY2022FY2023: net loss $1.16B on revenue $4.50B$4.50BFY2023FY2024: net loss $1.22B on revenue $4.37B$4.37BFY2024FY2025 Revenue: $4.34B — margin split not shown (non-operating gains)$4.34BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-02
  • 2026-07-02Ullem Scott B.A167$24.9K
  • 2026-07-02Meister Keith A.A142$21.2K
  • 2026-06-25Davies Scott MChief Legal OfficerSELL-615$110.7K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • BlackRock, Inc.15,825,678$1.95B-13.6%
  • Capital World Investors15,549,960$1.92B-22.6%
  • VANGUARD GROUP INC14,207,175$1.86B-2.9%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Illumina, Inc. do?

The company provides sequencing and array-based solutions for genetic and genomic analysis used by research centers, academic institutions, government laboratories, hospitals, and pharmaceutical and biotechnology companies.

What is ILMN's valuation?

ILMN trades at $188.68, 34.62× trailing earnings, 28.80× EV/EBITDA, as of 2026-07-15.

When did ILMN last file with the SEC?

Illumina, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 03:54 UTC. This page is also available as JSON at /api/data?ticker=ILMN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ILMN and 3,500+ tickers.

Create a free account — keep ILMN
For your agent
GET /api/data?ticker=ILMN

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt